Diagnostic performance of WINROP + surfactant therapy in predicting of type 1 ROP_ Tabela IV_ Diagnostyczna skuteczność WINROP + terapia surfaktantem w przewidywaniu ROP typu 1_
| Type 1 ROP | Non-type 1 ROP | |
|---|---|---|
| WINROP | 26 | 19 |
| WINROP | 1 | 33 |
| Sensitivity, % (95%CI) | 96.30 (81.03-99.91) | |
| Specificity, % (95%CI) | 63.46 (48.96-76.38) | |
| PPV, % (95%CI) | 57.78 (48.70-66.36) | |
| NPV, % (95%CI) | 97.06 (82.67-99.56) | |
| Cohen’s kappa coefficient | 0,51 | |
| AUC, (95%CI) | 0.80 (0.69-0.88) | |
Characteristics of the participating preterm infants_ Tabela I_ Charakterystyka grupy wcześniaków włączonych do badania_
| Characteristic Charakterystyka | All Wszyscy n = 79 | Non-type 1 ROP ROP typu innego niż 1 n=52 | Type 1 ROP ROP typu 1 n=27 | p value wartość p |
|---|---|---|---|---|
| Gender, male, n (%) | 49 (62) | 31 (60) | 18 (67) | 0.3591 |
| Gestational age, weeks, median (IQR) | 28 (26-30) | 29 (28-30,5) | 26 (25-27) | <0.0011 |
| Birth weight, g, median (IQR) | 1095 (900-1315) | 1216 (1055-1396,5) | 893 (760-1000) | <0.0011 |
| CRIB II score, median (IQR) | 7 (5-9) | 6 (4-7) | 9 (8-11) | 0.0011 < |
| GCS prenatal, n (%) | 47 (59) | 27 (52) | 20 (74) | 0.0472 |
| Surfactant, n (%) | 44 (56) | 24 (46) | 20 (74) | 0.0162 |
| IVH grade III or IV, n (%) | 9 (11) | 4 (8) | 5 (19) | 0.1442 |
| PDA ibu, n (%) | 35 (44) | 18 (35) | 17 (63) | 0.0152 |
| PDA lig, n (%) | 12 (15) | 3 (6) | 9 (33) | 0.0022 |
| Hyperglycaemia, Hiperglikemia*, n (%) | 10 (13) | 5 (10) | 5 (19) | 0.2522 |
| Sepsis, n (%) | 38 (48) | 21 (40) | 17 (63) | 0.0472 |
| NEC, n (%) | 4 (5) | 3 (6) | 1 (4) | 0.5772 |
| BPD, n (%) | 21 (27) | 6 (12) | 15 (56) | <0.0012 |
| Birth defects, n (%) | 11 (14) | 7 (13) | 4 (15) | 0.5572 |
Characteristics of 5 infants who developed type 1 ROP in the low-risk alarm group_ Tabela II_ Charakterystyka 5 noworodków które rozwinęły ROP typu 1 z grupy alarmu niskiego ryzyka_
| Gender Płeć | Gestational age, weeks Wiek ciążowy, tygodnie | Birth weight Masa urodzeniowa (g) | BPD Dysplazja oskrzelowo-płucna | Sepsis Sepsa | Surfactant Surfaktant | Hyperglycemia Hiperglikemia | Anaemia Niedokrwistość | IVH Krwawienia dokomorowe | |
|---|---|---|---|---|---|---|---|---|---|
| 1 | Male | 26 | 1130 | + | + | + | - | + | + |
| 2 | Female | 26 | 1050 | - | - | + | - | - | - |
| 3 | Male | 28 | 1270 | - | - | - | - | - | - |
| 4 | Male | 24 | 800 | + | - | + | - | + | + |
| 5 | Male | 23 | 720 | + | + | + | - | + | + |
Diagnostic performance of WINROP in predicfing the type 1 ROP_ Tabela III_ Diagnostyczna skuteczność WINROP w przewidywaniu ROP typu 1
| Type 1 ROP | Non-type 1 ROP | |
|---|---|---|
| WINROP | 22 | 15 |
| WINROP | 5 | 37 |
| Sensitivity, % (95% CI) | 81.48 (61.92-93.70) | |
| Specificity, % (95% CI) | 71.15 (56.92-82.87) | |
| PPV, % (95% CI) | 59.46 (48.08-69.91) | |
| NPV, % (95% CI) | 88.10 (76.70-94.33) | |
| Cohen’s kappa coefficient | 0.483 | |
| AUC, (95% CI) | 0.76 (0.65 to 0.85) | |